Category: Pharmaceuticals
-
InnoCan Pharma’s (CSE: INNO) investment potential in the Pharmaceuticals Sector: A Balanced View
InnoCan Pharma Corporation, trading on the Canadian Securities Exchange under the symbol INNO, FSE: IP4, and OTC: INNPF, is a pharmaceutical technology company that has garnered attention in the investment community. This article evaluates its potential as an investment option in the pharmaceuticals space, considering both its recent achievements and challenges. Business Model and Strategic…
-
Bionxt Solutions (BNXT.C) shows how pivots don’t have to mean resets
Several years back, Hugh Rogers was in my office talking about his cannabis company. Way back then, the plan was to grow in Germany and be first on the continent, using an old wartime bunker as a ‘safe growing facility’. Those plans morphed quickly as the reality of the cannabis space became clear. The cannabis…
-
Revive Therapeutics (RVV.C) finds multiple research options moving forward
In Canada, if you look backwards over the timeline, you’ll often find public companies have been other things back in the day. Risen, fallen, tapped out, rolled back, reemerged as a whole new thing. Sometimes this happens several times before a business model catches. Revive Therapeutics (RVV.C) is that rare Canadian smallcap that, while it…
-
Lucy Loves Luchre: Medexus Pharmaceuticals (MDP.T) is growing fast, keeping the bottom line trim
Hey y’all, Lucy Copperpot back for more analysis of Equity.Guru companies – this one is no longer on the client list, but I asked for permission to dig in anyway because I really think a ton of risk has been removed from Medexus Pharmaceuticals (MDP.T) that the market hasn’t factored in, and that’s a real…
-
Revive Therapeutics (RVV.C) licenses patent on long COVID biomarkers
Revive Therapeutics (RVV.C), a company that specializes in creating treatments and tests for diseases that don’t have many existing options available, has made a deal with a health research group called Lawson Health Research Institute to license the rights to use special signals in the blood—called biomarkers—that can show if someone has ‘long COVID.’ “We…
-
Revive Therapeutics (RVV.C): Covid came, Covid went, but Revive is still fighting
Back at the dawn of Covid-19, a load of public companies started pumping out news releases that claimed they were going to be entering the medical space. In the best tradition of Howe Street, long dormant mining companies suddenly became med-tech deals, hawking everything from clear plastic checkout counter dividers to virus sniffing doorways to…
-
Multi-Company Wrap: Watching the watchlist so you don’t have to
We have some 29 companies on our watchlist, all in a variety of sectors, that we’re covering at any one time. Some are clients, some not, some are on deaths door, some are skyrocketing, so we’ve decided to wrap them all up into one monthly wrap so you can keep track of everything at once.…
-
Pubco cocaine is here: What does it mean, who’s in, and who’s real?
I recently listened to a podcast episode of Search Engine with PJ Vogt, and I REALLY got into it. The episode was titled, “Why are drug dealers putting fentanyl in everything?” I’d asked myself the same question many times – why kill your customers? I’d recommend you go listen because the answer is a lot…
-
The Core Story: Medexus Pharmaceutical (MDP.T) just grows and grows
Continuing out Core Story program, today’s exploration is a company we just can’t get enough of, Medexus Pharmaceuticals (MDP.T). CEO Ken D’Entremont has nailed his milestones the last 18 months, continued running revenues up, kept expenses low, and restructured convertible debt to remain in control os his company’s direction going forward. They’ve blasted through a…
-
Innovation and Growth: Canada’s Thriving Pharmaceutical Industry in the Global Market
Even though the COVID-19 pandemic posed challenges for healthcare and life sciences companies, Canada’s pharmaceutical industry continued to thrive, thanks to the government’s investments in pharma which buttressed the industry against the storm. Comprising a 2.1% share of the global pharmaceutical market, Canada now ranks as the 9th largest market worldwide. There’s no resting on…